Ruinemans-KoertsJPeterse-StienissenIVerbruggenB.Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors. Thromb Haemost. 2010;104(5):1080-1082. doi:10.1160/TH09-12-0812.
2.
KovacsGOlschewskiH.The definition of pulmonary hypertension: history, practical implications and current controversies. Breathe. 2021;17(3):210076. doi:10.1183/20734735.0076-2021.
3.
EisenmengerV.Die angeborenen defekte der kammerscheidewand des herzens. Z Klin Med. 1897;32:1-28.
4.
WoodP.The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 1958;2(5099):755-762. doi:10.1136/bmj.2.5099.755.
5.
ArvanitakiAGiannakoulasGBaumgartnerHLammersAE.Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020;106(21):1638-1645. doi:10.1136/heartjnl-2020-316665.
6.
DillerGPGatzoulisMA.Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115(8):1039-1050. doi:10.1161/CIRCULATIONAHA.105.592386.
7.
KiddLDriscollDJGersonyWM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation. 1993;87(2 suppl):I38-I51.
8.
VongpatanasinWBricknerMEHillisLDLangeRA.The Eisenmenger syndrome in adults. Ann Intern Med. 1998;128(9):745-755. doi:10.7326/0003-4819-128-9-199805010-00008.
9.
MarelliAJMackieASIonescu-IttuRRahmeEPiloteL.Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007;115(2):163-172. doi:10.1161/CIRCULATIONAHA.106.627224.
10.
DillerGPKörtenMABauerUM, et al. Current therapy and outcome of Eisenmenger syndrome: data of the German national register for congenital heart defects. Eur Heart J. 2016;37(18):1449-1455. doi:10.1093/eurheartj/ehv743.
11.
EngelfrietPBoersmaEOechslinE, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. Eur Heart J. 2005;26(21):2325-2333. doi:10.1093/eurheartj/ehi3966.
12.
ArvanitakiAGatzoulisMAOpotowskyAR, et al. Eisenmenger syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(12):1183-1198. doi:10.1016/j.jacc.2022.01.022.
13.
van LoonRLRoofthooftMTHillegeHL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011;124(16):1755-1764. doi:10.1161/CIRCULATIONAHA.110.969584.
14.
HaworthSGHislopAA.Treatment and survival in children with pulmonary arterial hypertension: the UK pulmonary hypertension service for children 2001-2006. Heart. 2009;95(4):312-317. doi:10.1136/hrt.2008.150086.
15.
ChaixMAGatzoulisMADillerGPKhairyPOechslinEN.Eisenmenger syndrome: a multisystem disorder-do not destabilize the balanced but fragile physiology. Can J Cardiol. 2019;35(12):1664-1674. doi:10.1016/j.cjca.2019.10.002.
16.
WestburySKLeeKReilly-StittCTullohRMumfordAD.High haematocrit in cyanotic congenital heart disease affects how fibrinogen activity is determined by rotational thromboelastometry. Thromb Res. 2013;132(2):e145-e151. doi:10.1016/j.thromres.2013.07.006.
17.
JensenASJohanssonPIBochsenL, et al. Fibrinogen function is impaired in whole blood from patients with cyanotic congenital heart disease. Int J Cardiol. 2013;167(5):2210-2214. doi:10.1016/j.ijcard.2012.06.019.
18.
HenrikssonPVärendhGLundströmNR.Haemostatic defects in cyanotic congenital heart disease. Br Heart J. 1979;41(1):23-27. doi:10.1136/hrt.41.1.23.
19.
OechslinEKiowskiWSchindlerRBernheimAJuliusBBrunner-La RoccaHP.Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation. 2005;112(8):1106-1112. doi:10.1161/CIRCULATIONAHA.105.534073.
20.
WaldowHCWesthoff-BleckMWideraCTemplinCvon DepkaM.Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol. 2014;176(3):739-745. doi:10.1016/j.ijcard.2014.07.104.
MehtaRAtharMGirgisSHassanABeckerRC.Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians. J Thromb Thrombolysis. 2019;48(1):14-26. doi:10.1007/s11239-019-01849-2.
23.
HoriuchiHDomanTKokameKSaikiYMatsumotoM.Acquired von Willebrand syndrome associated with cardiovascular diseases. J Atheroscler Thromb. 2019;26(4):303-314. doi:10.5551/jat.RV17031.
24.
van GenderenPJVinkTMichielsJJvan’t VeerMBSixmaJJvan VlietHH.Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood. 1994;84(10):3378-3384.
25.
DalientoLSomervilleJPresbiteroP, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998;19(12):1845-1855. doi:10.1053/euhj.1998.1046.
26.
GalièNBeghettiMGatzoulisMA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54. doi:10.1161/CIRCULATIONAHA.106.630715.
27.
GatzoulisMALandzbergMBeghettiM, et al. Evaluation of macitentan in patients with Eisenmenger syndrome. Circulation. 2019;139(1):51-63. doi:10.1161/CIRCULATIONAHA.118.033575.
28.
BarstRJIvyDDGaitanG, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324-334. doi:10.1161/CIRCULATIONAHA.110.016667.
29.
KrishnanUTakatsukiSIvyDD, et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol. 2012;110(11):1704-1709. doi:10.1016/j.amjcard.2012.07.037.
30.
TayELPesetAPapaphylactouM, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011;151(3):307-312. doi:10.1016/j.ijcard.2010.05.066.
31.
Martínez-QuintanaEMiranda-CalderínGUgarte-LopeteguiARodríguez-GonzálezF.Rehabilitation program in adult congenital heart disease patients with pulmonary hypertension. Congenit Heart Dis. 2010;5(1):44-50.
32.
JonePNIvyDDHauckA, et al. Pulmonary hypertension in congenital heart disease: a scientific statement from the American heart association. Circ Heart Fail. 2023;16(7):e00080. doi:10.1161/HHF.0000000000000080.
